Estech Launches New Cobra Fusion System for Cardiac Endoscopic Ablation

New technology combines benefits of bipolar clamp with flexibility of endoscopically guided probe


October 12, 2012

Estech's Cobra Fusion ablation system is the first of its kind to use a unique suction application and innovative electrode configuration to gently pull the tissue targeted for ablation into the device and out of the path of circulating blood. The Cobra Fusion ablation system overcomes the most significant challenge faced in minimally invasive epicardial ablation, the cooling effect of the circulating blood inside the heart, and reproducibly creates transmural (full-thickness) lesions on a beating heart. This bipolar clamping technology in the form of an epicardial catheter is thus capable of creating linear lesions anywhere on a beating heart with unprecedented performance and ease of use.

The Cobra Fusion ablation system incorporates proprietary Versapolar technology — an exclusive innovation that delivers both bipolar and monopolar radiofrequency (RF) energy to the targeted cardiac tissue, enabling transmural lesion formation in thin and thick cardiac tissue. As with all Cobra ablation systems, the new device is powered by Estech’s patented temperature controlled radiofrequency (TCRF) energy, which continuously monitors and maintains tissue temperature at target levels throughout the procedure. TCRF avoids the need for multiple applications that other technologies often require and ensures that tissue temperatures remain within a safe and effective range.

The ablation system received U.S. Food and Drug Administration (FDA) clearance in April 2012 and CE mark in May 2012, and has been in extensive clinical evaluations in the United States and European Union since then.

For more information: